$BIOCQ
Biocept Inc Stock $biocq

$biocq Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000156459022013599 Filed on April 05, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$13.98M	$61.25M	$18.51M
YoY Change	-24.49%	123.04%	937.71%
Cost Of Revenue	$10.03M	$37.76M	$10.01M
YoY Change	0.21%	76.96%	248.78%
Gross Profit	$3.945M	$23.49M	$8.500M
YoY Change	-53.59%	283.74%	-879.82%
Gross Profit Margin	28.23%	38.34%	45.92%
Selling, General & Admin	$5.244M	$20.93M	$5.300M
YoY Change	-1.07%	27.88%	55.88%
% of Gross Profit	132.92%	89.14%	62.35%
Research & Development	$1.477M	$5.000M	$1.230M
YoY Change	20.06%	-3.85%	6.03%
% of Gross Profit	37.44%	21.29%	14.47%
Depreciation & Amortization	$448.2K	$1.530M	$250.0K
YoY Change	79.26%	40.37%	4.17%
% of Gross Profit	11.36%	6.51%	2.94%
Operating Expenses	$6.720M	$5.000M	$6.530M
YoY Change	2.91%	-3.85%	43.2%
Operating Profit	-$2.776M	$18.49M	$1.970M
YoY Change	-240.89%	-219.5%	-134.87%
Interest Expense	-$70.57K	$290.0K	-$60.00K
YoY Change	17.62%	-220.83%	0.0%
% of Operating Profit		1.57%	-3.05%
Other Income/Expense, Net	$0.00	-$290.0K	$0.00
YoY Change		-86.19%
Pretax Income	-$2.846M	-$2.699M	$1.900M
YoY Change	-249.8%	-84.85%	-133.27%
Income Tax	$125.0K	$125.0K
% Of Pretax Income
Net Earnings	-$2.971M	-$2.800M	$1.900M
YoY Change	-256.37%	-84.27%	-133.27%
Net Earnings / Revenue	-21.26%	-4.57%	10.26%
Basic Earnings Per Share		-$0.19
Diluted Earnings Per Share	-$176.5K	-$191.1K	$257.5K
COMMON SHARES
Basic Shares Outstanding		14.78M
Diluted Shares Outstanding		14.78M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.86M	$28.86M	$14.37M
YoY Change	100.86%	100.86%	54.52%
Cash & Equivalents	$28.86M		$14.37M
Short-Term Investments
Other Short-Term Assets	$391.0K	$391.0K	$2.150M
YoY Change	-81.81%	-81.81%	616.67%
Inventory	$2.651M	$2.651M	$1.930M
Prepaid Expenses
Receivables	$13.79M	$13.79M	$14.15M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$45.69M	$45.69M	$32.60M
YoY Change	40.18%	40.2%	134.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.401M	$14.27M	$2.318M
YoY Change	3.58%	-1.12%	54.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$456.0K	$456.0K	$426.0K
YoY Change	7.04%	6.05%
Total Long-Term Assets	$14.73M	$14.73M	$14.86M
YoY Change	-0.9%	-0.91%	286.92%
TOTAL ASSETS
Total Short-Term Assets	$45.69M	$45.69M	$32.60M
Total Long-Term Assets	$14.73M	$14.73M	$14.86M
Total Assets	$60.42M	$60.42M	$47.45M
YoY Change	27.32%	27.33%	167.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.246M	$7.246M	$8.366M
YoY Change	-13.39%	-13.33%	315.84%
Accrued Expenses	$3.018M	$3.444M	$3.166M
YoY Change	-4.67%	8.64%	59.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.083M	$1.083M	$960.0K
YoY Change	12.81%	12.81%	33.33%
Total Short-Term Liabilities	$11.77M	$11.77M	$12.50M
YoY Change	-5.79%	-5.74%	124.8%
LONG-TERM LIABILITIES
Long-Term Debt	$1.428M	$1.428M	$1.460M
YoY Change	-2.19%	-2.19%	50.52%
Other Long-Term Liabilities	$9.736M	$9.736M	$9.810M
YoY Change	-0.75%	-0.75%
Total Long-Term Liabilities	$11.16M	$11.16M	$11.27M
YoY Change	-0.94%	-0.94%	1061.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.77M	$11.77M	$12.50M
Total Long-Term Liabilities	$11.16M	$11.16M	$11.27M
Total Liabilities	$22.94M	$22.94M	$23.76M
YoY Change	-3.47%	-3.46%	263.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$266.4M		-$263.5M
YoY Change	1.09%		7.25%
Common Stock	$303.8M		$287.2M
YoY Change	5.78%		11.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.48M	$37.48M	$23.69M
YoY Change
Total Liabilities & Shareholders Equity	$60.42M	$60.42M	$47.45M
YoY Change	27.32%	27.33%	167.6%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$2.971M	-$2.800M	$1.900M
YoY Change	-256.37%	-84.27%	-133.27%
Depreciation, Depletion And Amortization	$448.2K	$1.530M	$250.0K
YoY Change	79.26%	40.37%	4.17%
Cash From Operating Activities	$1.563M	$800.0K	-$1.110M
YoY Change	-240.81%	-104.04%	-79.71%
INVESTING ACTIVITIES
Capital Expenditures	-$590.1K	$1.572M	-$810.0K
YoY Change	-27.15%	81.31%	84.09%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$590.1K	-$1.572M	-$810.0K
YoY Change	-27.15%	81.31%	84.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	192.7K	12.38M	-580.0K
YoY Change	-133.22%	-51.87%	-106.69%
NET CHANGE
Cash From Operating Activities	1.563M	800.0K	-1.110M
Cash From Investing Activities	-590.1K	-1.572M	-810.0K
Cash From Financing Activities	192.7K	12.38M	-580.0K
Net Change In Cash	1.166M	14.50M	-2.500M
YoY Change	-146.62%	186.09%	-190.58%
FREE CASH FLOW
Cash From Operating Activities	$1.563M	$800.0K	-$1.110M
Capital Expenditures	-$590.1K	$1.572M	-$810.0K
Free Cash Flow	$2.153M	-$772.0K	-$300.0K
YoY Change	-817.7%	-96.26%	-94.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	us-gaap	Unrecorded Unconditional Purchase Obligation Date UnrecordedUnconditionalPurchaseObligationDate	2020-05-31
CY2021	bioc	Period Of Change In Ownership PeriodOfChangeInOwnership	P3Y
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M9D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y21D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y21D
CY2021	dei	Auditor Firm AuditorFirmId	199
CY2021	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2020Q4	us-gaap	Cash Cash	14368000
CY2021Q4	us-gaap	Cash Cash	28864000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14145000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13786000
CY2020Q4	us-gaap	Inventory Net InventoryNet	1930000
CY2021Q4	us-gaap	Inventory Net InventoryNet	2651000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2152000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	391000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	32595000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	45692000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2318000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2401000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9776000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9026000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2338000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2842000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	426000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	456000
CY2020Q4	us-gaap	Assets Assets	47453000
CY2021Q4	us-gaap	Assets Assets	60417000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8366000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7246000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3166000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3018000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	426000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	964000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1083000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12496000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11773000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9805000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9736000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1460000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1428000
CY2020Q4	us-gaap	Liabilities Liabilities	23761000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	42000
CY2020	bioc	Adjustment To Additional Paid In Capital Warrant Inducement Expense AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense	2102000
CY2021Q4	us-gaap	Liabilities Liabilities	22937000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2111
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2111
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2106
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2106
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13397041
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13397041
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16849805
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16849805
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	287218000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	303829000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263527000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266351000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	23692000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37480000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47453000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60417000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61249000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-15469000
CY2021	us-gaap	Interest Expense InterestExpense	290000
CY2020	bioc	Warrant Inducement Expense WarrantInducementExpense	2102000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-290000
CY2020	bioc	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	3000
CY2021	bioc	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	0
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17810000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2824000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11201000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	941000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2402000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17807000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	23692000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2462000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	28000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000
CY2020	us-gaap	Profit Loss ProfitLoss	-17807000
CY2021	us-gaap	Profit Loss ProfitLoss	-2824000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1085000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1530000
CY2020	bioc	Amortization Of Right Of Use Assets AmortizationOfRightOfUseAssets	-84000
CY2021	bioc	Amortization Of Right Of Use Assets AmortizationOfRightOfUseAssets	1107000
CY2020	bioc	Increase Decrease In Inventory Reserve IncreaseDecreaseInInventoryReserve	-245000
CY2021	bioc	Increase Decrease In Inventory Reserve IncreaseDecreaseInInventoryReserve	-107000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	941000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2462000
CY2020	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	2102000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-4000
CY2021	bioc	Increase Decrease In Landlord Reimbursement IncreaseDecreaseInLandlordReimbursement	1856000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-505000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	426000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	29000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4465000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-411000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1185000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-147000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19786000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3690000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	867000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1572000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-867000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1572000
CY2020	bioc	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	24194000
CY2021	bioc	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	14120000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2402000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	28000
CY2020	bioc	Proceeds From Exercise Of Overallotment Warrants ProceedsFromExerciseOfOverallotmentWarrants	660000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	703000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1150000
CY2020	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	833000
CY2021	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	622000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25720000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12378000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5067000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14496000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9301000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14368000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14368000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28864000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	237000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	290000
CY2021	bioc	Financial Guarantee Insurance Contracts Premium Payable FinancialGuaranteeInsuranceContractsPremiumPayable	500000
CY2020	bioc	Financial Guarantee Insurance Contracts Premium Payable FinancialGuaranteeInsuranceContractsPremiumPayable	600000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1200000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1400000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	200000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and Business Activities </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was founded in California in May 1997 and <span style="color:#000000;">is a molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood and cerebral spinal fluid, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Further, sales to laboratory supply distributors of the Company’s proprietary SCTs commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world.</span></p> <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to evolve, and the extent to which COVID-19 may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, the emergence and impact of variants, vaccinations, government funding for COVID-19 testing, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. The Company experienced increased revenue levels in 2020 and 2021 related to its COVID-19 testing business.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"> </p>
CY2021Q4	us-gaap	Cash Cash	28900000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266400000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17800000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2800000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19800000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3700000
CY2021Q4	bioc	Aggregate Net Interest Bearing Indebtedness AggregateNetInterestBearingIndebtedness	2500000
CY2021Q4	bioc	Aggregate Net Interest Bearing Indebtedness Due Within One Year AggregateNetInterestBearingIndebtednessDueWithinOneYear	1100000
CY2021Q4	bioc	Other Non Interest Bearing Current Liabilities OtherNonInterestBearingCurrentLiabilities	10200000
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On September 3, 2020, pursuant to the approval of the Company’s board of directors, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock using a ratio of one-for-ten.
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to accounts receivable reserves, inventory reserves, long-lived assets, income taxes, including uncertain tax benefits, estimated transaction price for revenues, stock-based compensation, incremental borrowing rate estimates, and the determination of the Company’s ability to continue as a going concern. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Though the impact of the COVID-19 pandemic on the Company’s business and operating results presents additional uncertainty, the Company continues to use the best information available to determine its significant accounting estimates.</p>
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27461000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61249000
CY2020Q4	bioc	Gross And Net Accounts Receivable GrossAndNetAccountsReceivable	14145000
CY2021	bioc	Gross And Net Accounts Receivable For Amounts Recognized Upon Delivery GrossAndNetAccountsReceivableForAmountsRecognizedUponDelivery	235564000
CY2021	bioc	Gross And Net Accounts Receivable For Settlements Upon Adjudication GrossAndNetAccountsReceivableForSettlementsUponAdjudication	-235923000
CY2021Q4	bioc	Gross And Net Accounts Receivable GrossAndNetAccountsReceivable	13786000
CY2019Q4	bioc	Gross And Net Accounts Receivable GrossAndNetAccountsReceivable	3527000
CY2020	bioc	Gross And Net Accounts Receivable For Amounts Recognized Upon Delivery GrossAndNetAccountsReceivableForAmountsRecognizedUponDelivery	27462000
CY2020	bioc	Gross And Net Accounts Receivable For Settlements Upon Adjudication GrossAndNetAccountsReceivableForSettlementsUponAdjudication	-16844000
CY2020Q4	bioc	Gross And Net Accounts Receivable GrossAndNetAccountsReceivable	14145000
CY2021Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	4500000
CY2020Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	3500000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1100000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1500000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the years ended December 31, 2020 and 2021 were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage/CARES Act</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, as of December 31, 2020 and 2021 were as follows: </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage/CARES Act</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable business segment and historically has derived most revenues only from within the United States.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain components used in the Company’s current or planned products are currently sourced from one supplier, for which alternative suppliers exist but the Company has not validated the product(s) of such alternative supplier(s), and substitutes for these components may not be obtained easily or may require substantial design or manufacturing modifications. </p>
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021	us-gaap	Concentration Risk Supplier ConcentrationRiskSupplier	one supplier
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5200000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5000000.0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1900000
CY2020	bioc	Warrant Inducement Expense WarrantInducementExpense	2100000
CY2020Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2300000
CY2020Q1	us-gaap	Share Price SharePrice	4.00
CY2020Q1	bioc	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	8600000
CY2020Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1600000
CY2020Q1	us-gaap	Share Price SharePrice	4.10
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2230000
CY2020Q2	us-gaap	Share Price SharePrice	4.60
CY2020Q2	bioc	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	9600000
CY2020Q1	bioc	Estimated Grant Date Fair Value Of Warrants EstimatedGrantDateFairValueOfWarrants	2.80
CY2020Q1	bioc	Unregistered Warrants Issued Grant Date Fair Value UnregisteredWarrantsIssuedGrantDateFairValue	1900000
CY2019Q1	bioc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	12.00
CY2019Q1	bioc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	12.50
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.495
CY2019Q1	bioc	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	2.70
CY2019Q1	bioc	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	2.70
CY2019Q1	bioc	Estimated Fair Value Of Warrants Increased EstimatedFairValueOfWarrantsIncreased	2.90
CY2019Q1	bioc	Estimated Fair Value Of Warrants Increased EstimatedFairValueOfWarrantsIncreased	3.00
CY2019Q1	bioc	Class Of Warrants Or Rights Eligible For Price Modification ClassOfWarrantsOrRightsEligibleForPriceModification	216725
CY2019Q1	bioc	Class Of Warrants Or Rights Eligible For Price Modification ClassOfWarrantsOrRightsEligibleForPriceModification	476000
CY2019Q1	bioc	Warrant Inducement Expense WarrantInducementExpense	60000
CY2019Q1	bioc	Warrant Inducement Expense WarrantInducementExpense	130000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1236000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2303000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	691000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	294000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	54000
CY2020Q4	us-gaap	Inventory Gross InventoryGross	1930000
CY2021Q4	us-gaap	Inventory Gross InventoryGross	2651000
CY2020Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2974000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3063000
CY2020Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	158000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	161000
CY2020Q4	bioc	Computer Equipment And Software Gross ComputerEquipmentAndSoftwareGross	2428000
CY2021Q4	bioc	Computer Equipment And Software Gross ComputerEquipmentAndSoftwareGross	2931000
CY2020Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	570000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	634000
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	761000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	245000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6891000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7034000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4573000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4633000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2318000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2401000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	452000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	725000
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	869000
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	961000
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1022000
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	178000
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	457000
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	600000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	366000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	554000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3166000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3018000
CY2020Q1	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	197000000
CY2020Q1	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	4532000
CY2020Q1	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	265000000
CY2020Q1	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2025-01
CY2020Q1	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	11000000
CY2020Q1	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	48
CY2020Q1	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2020Q1	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2020Q1	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	288000
CY2020Q1	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	14000000
CY2020Q1	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2024-02
CY2020Q2	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	161000000
CY2020Q2	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	60
CY2020Q2	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	3337000
CY2020Q2	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	185000000
CY2020Q2	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2025-03
CY2020Q2	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	334000000
CY2020Q2	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2020Q2	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	8966000
CY2020Q2	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	469000000
CY2020Q2	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2025-06
CY2020Q3	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	143000000
CY2020Q3	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	60
CY2020Q3	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2020Q3	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2025-07
CY2020Q3	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	226000000
CY2020Q3	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2020Q3	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	16427000
CY2020Q3	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	261000000
CY2020Q4	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	192000000
CY2020Q4	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	48
CY2020Q4	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2020Q4	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	5382000
CY2020Q4	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	258000000
CY2020Q4	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2024-10
CY2020Q4	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	73000000
CY2020Q4	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	60
CY2020Q4	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2020Q4	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	84000000
CY2020Q4	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2025-11
CY2020Q4	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	91000000
CY2020Q4	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2020Q4	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2023-12
CY2021Q1	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	309000000
CY2021Q1	bioc	Finance Lease Transaction Initial Payment FinanceLeaseTransactionInitialPayment	100000000
CY2021Q1	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	36
CY2021Q1	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2021Q1	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	7152000
CY2021Q1	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	357000000
CY2021Q1	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	182000000
CY2021Q1	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	60
CY2021Q1	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2021Q1	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	4237000
CY2021Q1	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	242000000
CY2021Q1	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2026-02
CY2021Q1	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	186000000
CY2021Q1	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	60
CY2021Q1	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2021Q1	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	4735000
CY2021Q1	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	284000000
CY2021Q1	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2026-03
CY2021Q2	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	218000000
CY2021Q2	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2021Q2	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	282000000
CY2021Q2	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2024-03
CY2021Q3	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	125000000
CY2021Q3	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2021Q3	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	3471000
CY2021Q3	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	148000000
CY2021Q3	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2024-11
CY2021Q3	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	218000000
CY2021Q3	bioc	Finance Lease Transaction Number Of Installment Payments FinanceLeaseTransactionNumberOfInstallmentPayments	36
CY2021Q3	bioc	Finance Lease Transaction Frequency Of Periodic Payment FinanceLeaseTransactionFrequencyOfPeriodicPayment	monthly
CY2021Q3	bioc	Finance Lease Transaction Monthly Rental Payments FinanceLeaseTransactionMonthlyRentalPayments	7534000
CY2021Q3	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	271000000
CY2021Q3	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2024-07
CY2021	bioc	Proceeds From Lender To Fund Finance Lease Obligation ProceedsFromLenderToFundFinanceLeaseObligation	1200000
CY2021Q4	bioc	Finance Lease Transaction Amount Due Under Financing Arrangement FinanceLeaseTransactionAmountDueUnderFinancingArrangement	1600000
CY2021	bioc	Finance Lease Transaction Commitment Obligation Month And Year FinanceLeaseTransactionCommitmentObligationMonthAndYear	2026-03
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2021Q4	bioc	Reimbursable Leasehold Improvement Costs ReimbursableLeaseholdImprovementCosts	1800000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9776000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9026000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2338000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2842000
CY2020Q4	bioc	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	12114000
CY2021Q4	bioc	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	11868000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1428000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	426000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	964000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1083000
CY2020Q4	bioc	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	964000
CY2021Q4	bioc	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	1509000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9805000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9736000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1460000
CY2020Q4	bioc	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	11265000
CY2021Q4	bioc	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	11164000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	694000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	863000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	228000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	277000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1412000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1656000
CY2020	bioc	Operating And Finance Lease Cost OperatingAndFinanceLeaseCost	2334000
CY2021	bioc	Operating And Finance Lease Cost OperatingAndFinanceLeaseCost	2796000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1144000
CY2021Q4	bioc	Finance Leases Maintenance And Sales Tax Obligation Payments Due Next Twelve Months FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueNextTwelveMonths	111000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1586000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	996000
CY2021Q4	bioc	Finance Leases Maintenance And Sales Tax Obligation Payments Due In Two Years FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInTwoYears	95000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1629000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	539000
CY2021Q4	bioc	Finance Leases Maintenance And Sales Tax Obligation Payments Due In Three Years FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInThreeYears	61000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1672000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	188000
CY2021Q4	bioc	Finance Leases Maintenance And Sales Tax Obligation Payments Due In Four Years FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInFourYears	15000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1715000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	21000
CY2021Q4	bioc	Finance Leases Maintenance And Sales Tax Obligation Payments Due In Five Years FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInFiveYears	2000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1762000
CY2021Q4	bioc	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	8518000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2888000
CY2021Q4	bioc	Finance Leases Maintenance And Sales Tax Obligation Payments Due FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue	284000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16882000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	377000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6721000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2511000
CY2021Q4	bioc	Finance Leases Maintenance And Sales Tax Obligation Payments Net FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsNet	284000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10161000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	228000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	277000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1512000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	549000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	703000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1150000
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y6M
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.163
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.120
CY2021	bioc	Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans	2
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	273418
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.14
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	858523
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.51
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	53237
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	22.26
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1078704
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.64
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1558510
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.96
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	537
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	223483
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.83
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2413194
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.04
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2367847
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.10
CY2021Q4	bioc	Common Stock Warrants Outstanding Intrinsic Value CommonStockWarrantsOutstandingIntrinsicValue	16000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2122582
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4878334000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19711749000
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13333427
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11324289
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13333427
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11324289
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.74
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.74
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	250000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	283000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	125000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	125000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	125000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3739000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-567000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-940000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	66000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	101000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	278000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	94000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	178000
CY2020	bioc	Income Tax Reconciliation Warrant Inducement Expense IncomeTaxReconciliationWarrantInducementExpense	441000
CY2020	bioc	Income Tax Reconciliation Expiration Of Net Operating Losses IncomeTaxReconciliationExpirationOfNetOperatingLosses	912000
CY2021	bioc	Income Tax Reconciliation Expiration Of Net Operating Losses IncomeTaxReconciliationExpirationOfNetOperatingLosses	594000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	370000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	377000
CY2021	bioc	Income Tax Reconciliation Unrecognized Tax Benefits IncomeTaxReconciliationUnrecognizedTaxBenefits	2956000
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	-164000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	-480000
CY2021	bioc	Income Tax Reconciliation Section Three Eight Two Limitation IncomeTaxReconciliationSectionThreeEightTwoLimitation	-485000
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	7000
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-8000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-875000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	28000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4533000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2058000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	125000
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	13900000
CY2021	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	which will begin to expire in 2022
CY2020	bioc	Percent Of Uncertain Income Tax Positions Recognized PercentOfUncertainIncomeTaxPositionsRecognized	0.50
CY2021	bioc	Percent Of Uncertain Income Tax Positions Recognized PercentOfUncertainIncomeTaxPositionsRecognized	0.50
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3640000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	39000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3679000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18673000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18482000
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3689000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1026000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1824000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2516000
CY2020Q4	bioc	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	2394000
CY2021Q4	bioc	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	2821000
CY2020Q4	bioc	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	660000
CY2021Q4	bioc	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	368000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	860000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1164000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28100000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26377000
CY2020Q4	bioc	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2958000
CY2021Q4	bioc	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	3295000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2958000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3295000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25142000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23082000
CY2021Q4	bioc	Percentage Of Change In Ownership PercentageOfChangeInOwnership	0.50
CY2016Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	1100000
CY2021	bioc	Unconditional Purchase Commitment Frequency Of Periodic Payment UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment	quarterly
CY2021Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	0
CY2019Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	0
CY2020	bioc	Finance Leases Sales Tax And Maintenance Obligations Expense FinanceLeasesSalesTaxAndMaintenanceObligationsExpense	129000
CY2021	bioc	Finance Leases Sales Tax And Maintenance Obligations Expense FinanceLeasesSalesTaxAndMaintenanceObligationsExpense	130000
CY2021Q4	bioc	Finance Leases Maintenance And Sales Tax Obligation Payments Due FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue	300000

Files In Submission

Name	View Source	Status
0001564590-22-013599-index-headers.html	Edgar Link	pending
0001564590-22-013599-index.html	Edgar Link	pending
0001564590-22-013599.txt	Edgar Link	pending
0001564590-22-013599-xbrl.zip	Edgar Link	pending
bioc-10k_20211231.htm	Edgar Link	pending
bioc-10k_20211231_htm.xml	Edgar Link	completed
bioc-20211231.xsd	Edgar Link	pending
bioc-20211231_cal.xml	Edgar Link	unprocessable
bioc-20211231_def.xml	Edgar Link	unprocessable
bioc-20211231_lab.xml	Edgar Link	unprocessable
bioc-20211231_pre.xml	Edgar Link	unprocessable
bioc-ex1015_463.htm	Edgar Link	pending
bioc-ex1016_14.htm	Edgar Link	pending
bioc-ex1019_19.htm	Edgar Link	pending
bioc-ex1020_17.htm	Edgar Link	pending
bioc-ex108_526.htm	Edgar Link	pending
bioc-ex231_10.htm	Edgar Link	pending
bioc-ex311_9.htm	Edgar Link	pending
bioc-ex312_7.htm	Edgar Link	pending
bioc-ex321_6.htm	Edgar Link	pending
bioc-ex322_8.htm	Edgar Link	pending
bioc-ex43_527.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gjaxmdkuknt1000001.jpg	Edgar Link	pending
gjaxmdkuknt1000002.jpg	Edgar Link	pending
gjaxmdkuknt1000003.jpg	Edgar Link	pending
gz41imxwvdyo000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIOCQ
Biocept Inc Stock $biocq

2021 Q4 Form 10-K Financial Statement

#000156459022013599 Filed on April 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOCQ Biocept Inc Stock $biocq

2021 Q4 Form 10-K Financial Statement

#000156459022013599 Filed on April 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOCQ
Biocept Inc Stock $biocq